37 results about "Colorectal adenocarcinoma" patented technology

A method and apparatus for determining the progressive potential of a disease is disclosed. The forward to backward propagating second harmonic generation signal derived from a second harmonic generation instrument is used to assess the collagen microstructure of imaged body tissue by way of numerical values that are in turn used to determine the progressive or metastatic potential of the disease. The disease may, for example, be a cancer such as breast cancer, lung fibrosis, colorectal adenocarcinoma, or the like. The apparatus may include in vivo instruments or laboratory diagnostic instruments with methods disclosed herein.

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.

The invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, a preparing method, an application and a drug composite containing the compound thereof. More specifically, the invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound as shown in the formula I, a preparing method and an application thereof. By the growth inhibition test of various tumour cell lines (human breast cancer cells MDA-MB-435, p53-deleted poorly differentiated colorectal adenocarcinoma cells Hct116p53-/-, p53-enriched poorly differentiated colorectal adenocarcinoma cells Hct116p53+/+, human breast cancer cells Mcf-7, NIH189, human breast cancer cells SkBr-3, prostatic cancer cells LnCap, LnHer, human colorectal cancer cells HT29 and human ovarian cancer cellsHEY), the compound has favourable inhibition activity for the above tumour cells and can treat diseases caused by tumour cell malignant proliferation. The invention also discloses a drug composite containing the compound.

The invention discloses a method for determining an APRIL (A Proliferation-inducing Ligand) gene promoter and transcription factor binding site and use. According to the invention, a promoter region of APRIL is cloned and identified. As discovered, a region from -1539 to -1001 has an important effect on transcription adjustment and control over APRIL; a transcription factor Sp1 or NF-kB exits in the region; and the transcription of the APRIL gene can be activated. The invention provides application of mithramycin and Bay11-7082 to preparation of medicaments for treating human colorectal adenocarcinoma; and the effect is clear.

The present invention relates to in vitro methods and compositions for diagnosing and/or treating a colorectal adenocarcinoma associated with a chromosomal aberration on chromosome 20q and/or the predisposition for developing such an adenocarcinoma by determining the expression levels of a set of particular marker genes, wherein an elevated expression level of the marker genes in a test sample as compared to a control level is indicative of a colorectal adenocarcinoma.

The invention discloses Co-containing sandwich heteropolyacid as well as a synthesis method and application thereof, relating to heteropolyacid as well as synthesis method and application thereof. The invention provides a novel chemotherapy drug capable of resisting human colorectal adenocarcinoma and a synthesis method thereof. The molecular formula of the Co-containing sandwich heteropolyacid provided by the invention is H6[Bi2W20Co2(OH2)6O70Na4(OH2)14](C3H4N2)2. The synthesis method is as follow: firstly, dissolving Na2WO4 into water, heating and adjusting the pH value to obtain solution A; secondly, dissolving Bi(NO3)3, CoC12 and imidazole into the solution A at the same time to be uniformly mixed; heating to 80-120 DEG C and maintaining the temperature for 1-2h; and cooling, filtering and standing to obtain Co-containing sandwich heteropolyacid. The Co-containing sandwich heteropolyacid has the action of restraining the growth of cancer cells and the action of inducing death of the cancer cells. Therefore, the Co-containing sandwich heteropolyacid can be used as a chemotherapy drug for treatment of human colorectal adenocarcinoma.

The invention provides a monoclonal antibody, which has the following characteristics: 1) the antibody is IgMs immunoglobulin and the light-chain type of the antibody is k-typed; (2) the antigen is identified into a sugar-chain structure with sialylation mucoprotein surface; the monoclonal antibody can specifically identify colorectal adenocarcinoma, endometrial adenocarcinoma and pancreatic carcinoma tissues, can not identify the corresponding normal tissues. Specifically, the monoclonal antibody is formed by the secreting of hybridomas cells with the accession number of CGMCC No. 2643, the amino acid sequence in the heavy-chain variable zone is shown as SEQ ID NO: 1, the amino acid sequence in the light-chain variable zone is shown as SEQ ID NO: 2. The invention also provides a use of the monoclonal antibody in the preparation of a medicament or a kit, wherein the medicament or the kit can be used for the screening of cancer, early-stage diagnosis, treatment monitoring and tumour imaging. In addition, the invention provides a new antibody for inhibitting the growth of the tumor cells of colorectal carcinoma.

The invention discloses a matrine pyrimidine derivative, and a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The matrine pyrimidine derivative is a compound represented by a general formula (I) shown in the specification, or a compound represented by a general formula (II) shown in the specification. The matrine pyrimidine derivative disclosed by the invention has certain inhibitory activity on human tumor cells (human prostate cancer cells DU-145, human non-small cell lung cancer cells A549, human colorectal adenocarcinoma cells HCT15 and human cervical carcinoma cells HeLa), so that proliferation and differentiation of the tumor cells can be inhibited, and a new thought is provided for research and development of anti-tumor drugs; and the preparation method disclosed by the invention is simple, convenient and controllable, and the obtained product is high in yield and extremely high in purity.

The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules. The nucleic acid molecules used for diagnostics in the present invention are sequences from LOC 100526820, subsequently named CAHM (colorectal adenocarcinoma hypermethylated).

The invention discloses an application of magnolin in resisting colorectal cancer. Magnolin significantly inhibits the growth and proliferation of human colorectal cancer cells and human colorectal adenocarcinoma cells, significantly inhibits the growth of human colorectal cancer, and significantly inhibits the cell cycle of human colorectal cancer; magnolin promotes the autophagy of human colorectal cancer cells and human colorectal cancer. By blocking LIF/Stat3/Mcl-1 pathways, magnolin can promote the autophagy of the colorectal cancer cells and colorectal cancer, inhibits the proliferationof the colorectal cancer cells and blocks the period of the colorectal cancer cells. Magnolin has the activity of resisting human colorectal cancer cells and human colorectal cancer, and can be used for preparing products for resisting colorectal cancer or resisting the colorectal cancer cells.

The invention provides a polypeptide marker Pep5 enzyme-linked immunosorbent assay (ELISA) kit which contains a monoclonal antibody which is labeled by enzyme and secreted by monoclonal antibody hybridoma cell line with a China general microbiological culture collection center (CGMCC) No. 5269. The kit prepared by the monoclonal antibody secreted by the hybridoma cell line can be used for detecting colorectal adenocarcinoma, and is simple, convenient and rapid to operate, beneficial to high flux clinical detection and low in detection cost.

The invention discloses a human colorectal adenocarcinoma cell TRPV1 gene knockout cell strain and application. The cell strain is named as a human colorectal adenocarcinoma cell TRPV1 gene knockout cell strain CACO-2 KO, and was preserved in China Center for Type Culture Collection on December 25, 2019, and the preservation number is CCTCC NO. C202024. According to the invention, based on the CRISPR/cas9 technology, a plasmid vector constructed by using a pair of gRNAs represented by SEQ ID NO: 2-3 is adopted to electrically transfect a cell to be knocked out, and resistance and sequencing screening are performed to obtain the recombinant plasmid vector. The designed gRNA can accurately and efficiently knock out the TRPV1 gene, and a human colorectal adenocarcinoma cell line with the TRPV1 gene knocked out is effectively constructed. The establishment of the TRPV1 gene knockout cell line provides effective gene materials and gene tools for researching the action mechanism of capsaicine.

The invention discloses diosgenin hydroxamic acid derivatives as well as a preparation method and application thereof. Diosgenin is used as a lead compound, a series of hydroxamic acid derivatives are prepared through corresponding chemical reactions, and the application of the derivatives in the anti-tumor aspect is also disclosed. Pharmacological experiments show that all the synthesized diosgenin hydroximic acid derivatives are subjected to in-vitro anti-proliferative activity experiments on SW620 (human colonic adenocarcinoma cells), H358 (human non-small cell lung cancer cells), HCT-116 (human colorectal adenocarcinoma cells) and Aspc-1 (human metastatic pancreatic cancer cells) by adopting a CCK8 method. Experimental results show that the anti-tumor activity of most of the derivatives on cells is superior to that of diosgenin.

The invention relates to a diagnostic marker, in particular to a biological marker for detecting colorectal cancer and application thereof. Experiment and study find that a PAPPA (pregnancy-related plasma protein A) gene has obvious difference between the mRNA expression levels in colorectal adenocarcinoma tissues, mucinous colorectal adenocarcinoma tissues, cecal adenocarcinoma tissues, sigmoid colorectal carcinoma tissues and rectal adenocarcinoma tissues and the mRNA expression level in the tissues of healthy reference substances; the PAPPA protein expression level in serum of a colorectalcancer patient is significantly higher than the protein expression level in the serum of a normal person. The biological marker has the characteristics that the correlation between the PAPPA and the colorectal cancer is put forward for the first time; experiment proves that the PAPPA can be used for diagnosing the colorectal cancer; the operation is simple, the specificity is high, and the sensitivity is high.